Kardigan, Inc. (KARD) vs Kailera Therapeutics, Inc. (KLRA)

A side-by-side comparison of Kardigan, Inc. and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Kardigan, Inc. logo
KARD
Kardigan, Inc.
$1.28B
$14.28HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Kailera Therapeutics, Inc. logo
KLRA
Kailera Therapeutics, Inc.
$1.41B
$10.89HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT

Total return — KARD vs KLRA

growth of $100 · dividends reinvested · last 1y
KARD -30.7% (-30.7%/yr)KLRA -45.5% (-45.5%/yr)KARD compounded faster over this window
6080100120Start $100$69$54
KARD KLRA

KARD vs KLRA: by the numbers

  • •KLRA is the larger company ($1.41B vs $1.28B market cap).

Metrics side by side

Valuation

MetricKARDKLRA
P/B ratio2.071.26

Profitability

MetricKARDKLRA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROIC-57.11%-24.52%

Go deeper

Full KARD analysisFull KLRA analysisInteractive comparison tool

Dig into the metrics

Kardigan ROEKailera Therapeutics ROEKardigan operating marginKailera Therapeutics operating marginKardigan revenue growthKailera Therapeutics revenue growthKardigan free cash flowKailera Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.